IP6K1 and neoplasm: To examine if the deficiency of host IP6K1 in the tumor microenvironment leads to changes in lymphocytes or inflammatory cells during tumor progression, we harvested tumor-bearing tissues from IP6K1 KO and WT mice 2.5 weeks after the injection of MC38 cells and compared the type and quantity of infiltrating immune cells.